EXELIXIS INC's ticker is EXEL and the CUSIP is 30161Q104. A total of 376 filers reported holding EXELIXIS INC in Q2 2023. The put-call ratio across all filers is 0.08 and the average weighting 0.4%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2024 | $2,383,914 | -16.9% | 106,093 | -12.2% | 0.01% | -16.7% |
Q1 2024 | $2,867,820 | -6.9% | 120,853 | -5.9% | 0.01% | -14.3% |
Q4 2023 | $3,081,568 | +8.1% | 128,453 | -1.6% | 0.01% | -6.7% |
Q3 2023 | $2,851,210 | – | 130,490 | +63553.7% | 0.02% | – |
Q2 2023 | $0 | -100.0% | 205 | -99.9% | 0.00% | -100.0% |
Q4 2022 | $2,324 | -99.9% | 142,407 | -1.6% | 0.02% | -10.0% |
Q3 2022 | $2,363,000 | -26.3% | 144,792 | -1.4% | 0.02% | -23.1% |
Q2 2022 | $3,208,000 | -2.9% | 146,867 | +2.1% | 0.03% | +8.3% |
Q1 2022 | $3,305,000 | +27.6% | 143,777 | +1.1% | 0.02% | +26.3% |
Q4 2021 | $2,591,000 | -15.2% | 142,277 | -0.3% | 0.02% | +5.6% |
Q3 2021 | $3,054,000 | +0.3% | 142,707 | -16.7% | 0.02% | 0.0% |
Q2 2021 | $3,046,000 | -28.9% | 171,248 | -1.1% | 0.02% | -30.8% |
Q1 2021 | $4,284,000 | +6.5% | 173,220 | -4.7% | 0.03% | 0.0% |
Q4 2020 | $4,023,000 | -3.0% | 181,728 | -2.3% | 0.03% | -13.3% |
Q3 2020 | $4,147,000 | -10.7% | 186,027 | -0.5% | 0.03% | -16.7% |
Q2 2020 | $4,646,000 | +0.4% | 186,907 | +7.2% | 0.04% | -14.3% |
Q1 2020 | $4,626,000 | +53.5% | 174,355 | -0.5% | 0.04% | +82.6% |
Q4 2019 | $3,013,000 | +3.0% | 175,177 | +1.0% | 0.02% | 0.0% |
Q3 2019 | $2,924,000 | -22.3% | 173,441 | +0.0% | 0.02% | -23.3% |
Q2 2019 | $3,765,000 | -35.4% | 173,402 | -28.0% | 0.03% | -36.2% |
Q1 2019 | $5,828,000 | +30.1% | 240,951 | +24.4% | 0.05% | +23.7% |
Q4 2018 | $4,481,000 | +59.3% | 193,730 | +2.1% | 0.04% | +65.2% |
Q3 2018 | $2,813,000 | +1107.3% | 189,782 | +1633.3% | 0.02% | +1050.0% |
Q2 2018 | $233,000 | +3.6% | 10,949 | +2.6% | 0.00% | 0.0% |
Q1 2018 | $225,000 | -32.6% | 10,676 | -2.6% | 0.00% | 0.0% |
Q4 2017 | $334,000 | +14.0% | 10,965 | -2.3% | 0.00% | 0.0% |
Q3 2017 | $293,000 | -6.7% | 11,227 | +0.5% | 0.00% | 0.0% |
Q2 2017 | $314,000 | +390.6% | 11,167 | -38.0% | 0.00% | – |
Q1 2014 | $64,000 | -38.5% | 18,006 | +5.7% | 0.00% | -100.0% |
Q4 2013 | $104,000 | 0.0% | 17,027 | -4.8% | 0.00% | 0.0% |
Q3 2013 | $104,000 | +23.8% | 17,877 | -3.8% | 0.00% | 0.0% |
Q2 2013 | $84,000 | – | 18,577 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Meditor Group Ltd | 11,275,871 | $254,722,000 | 71.55% |
GREAT POINT PARTNERS LLC | 1,201,100 | $27,133,000 | 5.61% |
INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 886,534 | $20,027,000 | 5.30% |
Sargent Investment Group, LLC | 498,350 | $11,258,000 | 2.96% |
CAPITAL MANAGEMENT CORP /VA | 311,660 | $7,040,000 | 1.57% |
EULAV Asset Management | 2,460,000 | $55,571,000 | 1.49% |
CM Management, LLC | 80,000 | $1,807,000 | 1.34% |
Integral Health Asset Management, LLC | 200,000 | $4,518,000 | 1.29% |
FARALLON CAPITAL MANAGEMENT LLC | 10,750,000 | $242,843,000 | 1.21% |
Sofinnova Investments, Inc. | 839,181 | $18,957,000 | 1.14% |